CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Total revenues	$ 2,671,542	$ 552,473	$ 4,287,683	$ 1,185,992
Cost of revenues	356,610	179,582	599,172	411,613
Operating expenses:
Selling, general and administrative	3,557,487	2,285,544	7,058,391	4,658,957
Research and development	874,055	703,018	1,622,420	1,267,444
Depreciation and amortization	199,381	66,537	296,793	141,604
Total operating expenses	4,630,923	3,055,099	8,977,604	6,068,005
LOSS FROM OPERATIONS	(2,315,991)	(2,682,208)	(5,289,093)	(5,293,626)
Other (expense) income:
Interest income (expense), net	13,841	(29,096)	8,403	(58,187)
Loss on extinguishment of convertible notes payable			(1,774,662)	0
Gain on extinguishment of notes payable	839,945		839,945	0
Other expense, net	(54,873)	(239,601)	(108,733)	(261,833)
Loss before provision for income taxes	(1,517,078)	(2,950,905)	(6,324,140)	(5,613,646)
Provision for income taxes	0	0	0	0
NET LOSS	(1,517,078)	(2,950,905)	(6,324,140)	(5,613,646)
Less: Net loss (income) attributable to noncontrolling interest	278	(1,220)	(2,216)	(1,190)
NET LOSS attributable to Applied DNA Sciences, Inc.	(1,516,800)	(2,952,125)	(6,326,356)	(5,614,836)
Deemed dividend related to warrant modifications				(2,842)
NET LOSS applicable to common stockholders	$ (1,516,800)	$ (2,952,125)	$ (6,326,356)	$ (5,617,678)
Net loss per share applicable to common stockholders - basic and diluted	$ (0.21)	$ (0.79)	$ (1.00)	$ (1.76)
Weighted average shares outstanding - basic and diluted	7,235,031	3,758,512	6,341,590	3,196,616
Product
Revenues:
Total revenues	$ 965,110	$ 197,801	$ 1,515,207	$ 435,671
Service
Revenues:
Total revenues	$ 1,706,432	$ 354,672	$ 2,772,476	$ 750,321